PegBio Announces ADA 2026 Late-Breaking Abstract Acceptance for Once-Monthly GLP-1 Candidate CR059

Bulletin Express04-02

PegBio Co., Ltd. reported that its internally developed candidate CR059 has been accepted as a Late Breaking Abstract for poster presentation at the 2026 Scientific Sessions of the American Diabetes Association (ADA).

The abstract, titled “CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys,” highlights the molecule’s ability to deliver (1) significant weight-loss effects, (2) strong glucose-lowering performance, and (3) long-term expression from a single dose. Pre-clinical data suggest that, leveraging the company’s circRNA-LNP platform, CR059 could support dosing intervals of one month and potentially extend to quarterly administration.

Management views ADA acceptance as external validation of PegBio’s R&D capabilities and expects the exposure to enhance the project’s international academic profile. CR059 remains in the research phase; timelines for clinical trials, regulatory approval, and commercialization are subject to uncertainty.

PegBio stated it will continue advancing CR059 and other pipeline assets and will provide further updates in line with Hong Kong listing regulations. The announcement was authorized by Chairman and Executive Director Dr. Michael Min Xu on 2 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134587484?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134587484","market":"hk","top_or_hot":-1,"title":"PegBio Announces ADA 2026 Late-Breaking Abstract Acceptance for Once-Monthly GLP-1 Candidate CR059","media":"Bulletin Express","content":"<p>PegBio Co., Ltd. reported that its internally developed candidate CR059 has been accepted as a Late Breaking Abstract for poster presentation at the 2026 Scientific Sessions of the American Diabetes Association (ADA).</p>\n<p>The abstract, titled “CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys,” highlights the molecule’s ability to deliver (1) significant weight-loss effects, (2) strong glucose-lowering performance, and (3) long-term expression from a single dose. Pre-clinical data suggest that, leveraging the company’s circRNA-LNP platform, CR059 could support dosing intervals of one month and potentially extend to quarterly administration.</p>\n<p>Management views ADA acceptance as external validation of PegBio’s R&D capabilities and expects the exposure to enhance the project’s international academic profile. CR059 remains in the research phase; timelines for clinical trials, regulatory approval, and commercialization are subject to uncertainty.</p>\n<p>PegBio stated it will continue advancing CR059 and other pipeline assets and will provide further updates in line with Hong Kong listing regulations. The announcement was authorized by Chairman and Executive Director Dr. Michael Min Xu on 2 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PegBio Announces ADA 2026 Late-Breaking Abstract Acceptance for Once-Monthly GLP-1 Candidate CR059</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPegBio Announces ADA 2026 Late-Breaking Abstract Acceptance for Once-Monthly GLP-1 Candidate CR059\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-02 19:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PegBio Co., Ltd. reported that its internally developed candidate CR059 has been accepted as a Late Breaking Abstract for poster presentation at the 2026 Scientific Sessions of the American Diabetes Association (ADA).</p>\n<p>The abstract, titled “CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys,” highlights the molecule’s ability to deliver (1) significant weight-loss effects, (2) strong glucose-lowering performance, and (3) long-term expression from a single dose. Pre-clinical data suggest that, leveraging the company’s circRNA-LNP platform, CR059 could support dosing intervals of one month and potentially extend to quarterly administration.</p>\n<p>Management views ADA acceptance as external validation of PegBio’s R&D capabilities and expects the exposure to enhance the project’s international academic profile. CR059 remains in the research phase; timelines for clinical trials, regulatory approval, and commercialization are subject to uncertainty.</p>\n<p>PegBio stated it will continue advancing CR059 and other pipeline assets and will provide further updates in line with Hong Kong listing regulations. The announcement was authorized by Chairman and Executive Director Dr. Michael Min Xu on 2 April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1134587484","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134587484","pubTimestamp":1775129108,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"PegBio Co., Ltd. reported that its internally developed candidate CR059 has been accepted as a Late Breaking Abstract for poster presentation at the 2026 Scientific Sessions of the American Diabetes...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"PegBio宣布ADA 2026最新摘要接受每月一次的GLP-1候选药物CR059","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"PegBio Co., Ltd. reported that its internally developed candidate CR059 has been accepted as a Late Breaking Abstract for poster presentation at the 2026 Scientific Sessions of the American Diabetes Association (ADA).\nThe abstract, titled “CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys,” highlights the molecule’s ability to deliver (1) significant weight-loss effects, (2) strong glucose-lowering performance, and (3) long-term expression from a single dose. Pre-clinical data suggest that, leveraging the company’s circRNA-LNP platform, CR059 could support dosing intervals of one month and potentially extend to quarterly administration.\nManagement views ADA acceptance as external validation of PegBio’s R&D capabilities and expects the exposure to enhance the project’s international academic profile. CR059 remains in the research phase; timelines for clinical trials, regulatory approval, and commercialization are subject to uncertainty.\nPegBio stated it will continue advancing CR059 and other pipeline assets and will provide further updates in line with Hong Kong listing regulations. The announcement was authorized by Chairman and Executive Director Dr. Michael Min Xu on 2 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134587484","isCrawlerRequest":true}